ID   KAT6B_HUMAN             Reviewed;        2073 AA.
AC   Q8WYB5; O15087; Q86Y05; Q8WU81; Q9UKW2; Q9UKW3; Q9UKX0;
DT   05-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   10-MAY-2017, entry version 149.
DE   RecName: Full=Histone acetyltransferase KAT6B;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:10497217};
DE   AltName: Full=Histone acetyltransferase MOZ2;
DE   AltName: Full=MOZ, YBF2/SAS3, SAS2 and TIP60 protein 4;
DE            Short=MYST-4;
DE   AltName: Full=Monocytic leukemia zinc finger protein-related factor;
GN   Name=KAT6B; Synonyms=KIAA0383, MORF, MOZ2, MYST4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), TISSUE SPECIFICITY,
RP   AUTOACETYLATION, CATALYTIC ACTIVITY, DOMAIN, AND FUNCTION.
RC   TISSUE=Bone marrow;
RX   PubMed=10497217; DOI=10.1074/jbc.274.40.28528;
RA   Champagne N., Bertos N.R., Pelletier N., Wang A.H., Vezmar M.,
RA   Yang Y., Heng H.H., Yang X.-J.;
RT   "Identification of a human histone acetyltransferase related to
RT   monocytic leukemia zinc finger protein.";
RL   J. Biol. Chem. 274:28528-28536(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Borrow J., Housman D.E.;
RT   "Structure and function of the human MYST family: MOZ2, MYST1 and
RT   MYST2.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-322 AND 1187-2073.
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1136-1287, AND CHROMOSOMAL TRANSLOCATION
RP   WITH CREBBP.
RX   PubMed=11157802; DOI=10.1093/hmg/10.4.395;
RA   Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U.,
RA   Billstroem R., Stroembeck B., Mitelman F., Johansson B.;
RT   "Fusion of the MORF and CBP genes in acute myeloid leukemia with the
RT   t(10;16)(q22;p13).";
RL   Hum. Mol. Genet. 10:395-404(2001).
RN   [7]
RP   INTERACTION WITH RUNX1 AND RUNX2, AUTOACETYLATION, AND FUNCTION.
RX   PubMed=11965546; DOI=10.1038/sj.onc.1205367;
RA   Pelletier N., Champagne N., Stifani S., Yang X.-J.;
RT   "MOZ and MORF histone acetyltransferases interact with the Runt-domain
RT   transcription factor Runx2.";
RL   Oncogene 21:2729-2740(2002).
RN   [8]
RP   FUNCTION, AND IDENTIFICATION IN THE MOZ/MORF COMPLEX.
RX   PubMed=16387653; DOI=10.1016/j.molcel.2005.12.007;
RA   Doyon Y., Cayrou C., Ullah M., Landry A.-J., Cote V., Selleck W.,
RA   Lane W.S., Tan S., Yang X.-J., Cote J.;
RT   "ING tumor suppressor proteins are critical regulators of chromatin
RT   acetylation required for genome expression and perpetuation.";
RL   Mol. Cell 21:51-64(2006).
RN   [9]
RP   IDENTIFICATION IN THE MOZ/MORF COMPLEX, AND INTERACTION WITH BRPF1.
RX   PubMed=18794358; DOI=10.1128/MCB.01297-08;
RA   Ullah M., Pelletier N., Xiao L., Zhao S.P., Wang K., Degerny C.,
RA   Tahmasebi S., Cayrou C., Doyon Y., Goh S.-L., Champagne N., Cote J.,
RA   Yang X.-J.;
RT   "Molecular architecture of quartet MOZ/MORF histone acetyltransferase
RT   complexes.";
RL   Mol. Cell. Biol. 28:6828-6843(2008).
RN   [10]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1038; LYS-1042 AND LYS-1044,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [11]
RP   INVOLVEMENT IN SBBYSS, AND VARIANT LYS-360.
RX   PubMed=22077973; DOI=10.1016/j.ajhg.2011.10.008;
RA   Clayton-Smith J., O'Sullivan J., Daly S., Bhaskar S., Day R.,
RA   Anderson B., Voss A.K., Thomas T., Biesecker L.G., Smith P., Fryer A.,
RA   Chandler K.E., Kerr B., Tassabehji M., Lynch S.A.,
RA   Krajewska-Walasek M., McKee S., Smith J., Sweeney E., Mansour S.,
RA   Mohammed S., Donnai D., Black G.;
RT   "Whole-exome-sequencing identifies mutations in histone
RT   acetyltransferase gene KAT6B in individuals with the Say-Barber-
RT   Biesecker variant of Ohdo syndrome.";
RL   Am. J. Hum. Genet. 89:675-681(2011).
RN   [12]
RP   INVOLVEMENT IN GTPTS.
RX   PubMed=22265014; DOI=10.1016/j.ajhg.2011.11.023;
RA   Campeau P.M., Kim J.C., Lu J.T., Schwartzentruber J.A.,
RA   Abdul-Rahman O.A., Schlaubitz S., Murdock D.M., Jiang M.M.,
RA   Lammer E.J., Enns G.M., Rhead W.J., Rowland J., Robertson S.P.,
RA   Cormier-Daire V., Bainbridge M.N., Yang X.J., Gingras M.C.,
RA   Gibbs R.A., Rosenblatt D.S., Majewski J., Lee B.H.;
RT   "Mutations in KAT6B, encoding a histone acetyltransferase, cause
RT   Genitopatellar syndrome.";
RL   Am. J. Hum. Genet. 90:282-289(2012).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-355; SER-647 AND
RP   SER-1048, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-673, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [15]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-673, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [16]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-483.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Histone acetyltransferase which may be involved in both
CC       positive and negative regulation of transcription. Required for
CC       RUNX2-dependent transcriptional activation. May be involved in
CC       cerebral cortex development. Component of the MOZ/MORF complex
CC       which has a histone H3 acetyltransferase activity.
CC       {ECO:0000269|PubMed:10497217, ECO:0000269|PubMed:11965546,
CC       ECO:0000269|PubMed:16387653}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:10497217}.
CC   -!- SUBUNIT: Component of the MOZ/MORF complex composed at least of
CC       ING5, KAT6A, KAT6B, MEAF6 and one of BRPF1, BRD1/BRPF2 and BRPF3.
CC       Interacts with RUNX1 and RUNX2. {ECO:0000269|PubMed:11965546,
CC       ECO:0000269|PubMed:16387653, ECO:0000269|PubMed:18794358}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Beta;
CC         IsoId=Q8WYB5-1; Sequence=Displayed;
CC       Name=2; Synonyms=Alpha;
CC         IsoId=Q8WYB5-2; Sequence=VSP_014587;
CC       Name=3;
CC         IsoId=Q8WYB5-3; Sequence=VSP_014586;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with high levels in
CC       heart, pancreas, testis and ovary. {ECO:0000269|PubMed:10497217}.
CC   -!- DOMAIN: The N-terminus is involved in transcriptional activation
CC       while the C-terminus is involved in transcriptional repression.
CC       {ECO:0000269|PubMed:10497217}.
CC   -!- PTM: Autoacetylated (PubMed:10497217 and PubMed:11965546).
CC       Autoacetylation at Lys-815 is required for proper function.
CC       {ECO:0000250|UniProtKB:Q9H7Z6, ECO:0000269|PubMed:10497217,
CC       ECO:0000269|PubMed:11965546}.
CC   -!- DISEASE: Note=A chromosomal aberration involving KAT6B may be a
CC       cause acute myeloid leukemias. Translocation t(10;16)(q22;p13)
CC       with CREBBP. {ECO:0000269|PubMed:11157802}.
CC   -!- DISEASE: Ohdo syndrome, SBBYS variant (SBBYSS) [MIM:603736]: A
CC       syndrome characterized by distinctive facial appearance with
CC       severe blepharophimosis, an immobile mask-like face, a bulbous
CC       nasal tip, and a small mouth with a thin upper lip. The condition
CC       presents in infancy with severe hypotonia and feeding problems.
CC       Associated skeletal problems include joint laxity, abnormally long
CC       thumbs and great toes, and dislocated or hypoplastic patellae.
CC       Structural cardiac defects are present in around 50% of cases, and
CC       dental anomalies, including small and pointed teeth, are common.
CC       Optic atrophy and conductive or sensorineural deafness are
CC       repeatedly reported. Many affected individuals have abnormalities
CC       of thyroid structure or function. SBBYSS is usually associated
CC       with severe mental retardation, delayed motor milestones, and
CC       significantly impaired speech. {ECO:0000269|PubMed:22077973}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Genitopatellar syndrome (GTPTS) [MIM:606170]: A rare
CC       disorder consisting of microcephaly, severe psychomotor
CC       retardation, and characteristic coarse facial features, including
CC       broad nose and small or retracted chin, associated with congenital
CC       flexion contractures of the lower extremities, abnormal or missing
CC       patellae, and urogenital anomalies. {ECO:0000269|PubMed:22265014}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the MYST (SAS/MOZ) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAF00100.1; Type=Frameshift; Positions=550, 562; Evidence={ECO:0000305};
CC       Sequence=AAH14143.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH48199.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MYST4ID41488ch10q22.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF113514; AAF00095.1; -; mRNA.
DR   EMBL; AF119230; AAF00099.1; -; mRNA.
DR   EMBL; AF119231; AAF00100.1; ALT_FRAME; mRNA.
DR   EMBL; AF217500; AAL56647.1; -; mRNA.
DR   EMBL; AB002381; BAA20837.2; -; mRNA.
DR   EMBL; BC014143; AAH14143.1; ALT_SEQ; mRNA.
DR   EMBL; BC021128; AAH21128.1; -; mRNA.
DR   EMBL; BC048199; AAH48199.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS58084.1; -. [Q8WYB5-3]
DR   CCDS; CCDS58085.1; -. [Q8WYB5-2]
DR   CCDS; CCDS7345.1; -. [Q8WYB5-1]
DR   RefSeq; NP_001243397.1; NM_001256468.1. [Q8WYB5-2]
DR   RefSeq; NP_001243398.1; NM_001256469.1. [Q8WYB5-3]
DR   RefSeq; NP_036462.2; NM_012330.3. [Q8WYB5-1]
DR   RefSeq; XP_005269721.1; XM_005269664.2. [Q8WYB5-1]
DR   RefSeq; XP_016871489.1; XM_017016000.1. [Q8WYB5-1]
DR   RefSeq; XP_016871490.1; XM_017016001.1. [Q8WYB5-1]
DR   RefSeq; XP_016871491.1; XM_017016002.1. [Q8WYB5-1]
DR   RefSeq; XP_016871492.1; XM_017016003.1. [Q8WYB5-1]
DR   RefSeq; XP_016871494.1; XM_017016005.1. [Q8WYB5-2]
DR   RefSeq; XP_016871495.1; XM_017016006.1. [Q8WYB5-3]
DR   RefSeq; XP_016871496.1; XM_017016007.1. [Q8WYB5-3]
DR   RefSeq; XP_016871497.1; XM_017016008.1. [Q8WYB5-3]
DR   UniGene; Hs.35758; -.
DR   UniGene; Hs.599543; -.
DR   UniGene; Hs.740873; -.
DR   ProteinModelPortal; Q8WYB5; -.
DR   SMR; Q8WYB5; -.
DR   BioGrid; 117069; 10.
DR   IntAct; Q8WYB5; 54.
DR   MINT; MINT-2871056; -.
DR   STRING; 9606.ENSP00000287239; -.
DR   iPTMnet; Q8WYB5; -.
DR   PhosphoSitePlus; Q8WYB5; -.
DR   BioMuta; KAT6B; -.
DR   DMDM; 143811424; -.
DR   EPD; Q8WYB5; -.
DR   MaxQB; Q8WYB5; -.
DR   PaxDb; Q8WYB5; -.
DR   PeptideAtlas; Q8WYB5; -.
DR   PRIDE; Q8WYB5; -.
DR   Ensembl; ENST00000287239; ENSP00000287239; ENSG00000156650. [Q8WYB5-1]
DR   Ensembl; ENST00000372711; ENSP00000361796; ENSG00000156650. [Q8WYB5-2]
DR   Ensembl; ENST00000372714; ENSP00000361799; ENSG00000156650. [Q8WYB5-3]
DR   Ensembl; ENST00000372724; ENSP00000361809; ENSG00000156650. [Q8WYB5-3]
DR   Ensembl; ENST00000372725; ENSP00000361810; ENSG00000156650. [Q8WYB5-3]
DR   Ensembl; ENST00000628038; ENSP00000485896; ENSG00000281813. [Q8WYB5-3]
DR   Ensembl; ENST00000628523; ENSP00000487238; ENSG00000281813. [Q8WYB5-3]
DR   Ensembl; ENST00000629233; ENSP00000487219; ENSG00000281813. [Q8WYB5-3]
DR   Ensembl; ENST00000629879; ENSP00000486731; ENSG00000281813. [Q8WYB5-2]
DR   Ensembl; ENST00000630001; ENSP00000486595; ENSG00000281813. [Q8WYB5-1]
DR   GeneID; 23522; -.
DR   KEGG; hsa:23522; -.
DR   UCSC; uc001jwm.3; human. [Q8WYB5-1]
DR   CTD; 23522; -.
DR   DisGeNET; 23522; -.
DR   GeneCards; KAT6B; -.
DR   GeneReviews; KAT6B; -.
DR   HGNC; HGNC:17582; KAT6B.
DR   HPA; HPA006104; -.
DR   MalaCards; KAT6B; -.
DR   MIM; 603736; phenotype.
DR   MIM; 605880; gene.
DR   MIM; 606170; phenotype.
DR   neXtProt; NX_Q8WYB5; -.
DR   OpenTargets; ENSG00000156650; -.
DR   Orphanet; 3047; Blepharophimosis-intellectual disability syndrome, SBBYS type.
DR   Orphanet; 85201; Genitopatellar syndrome.
DR   Orphanet; 648; Noonan syndrome.
DR   PharmGKB; PA134880712; -.
DR   eggNOG; KOG2747; Eukaryota.
DR   eggNOG; COG5027; LUCA.
DR   GeneTree; ENSGT00550000074503; -.
DR   HOVERGEN; HBG052563; -.
DR   InParanoid; Q8WYB5; -.
DR   KO; K11306; -.
DR   OMA; FTPPMQL; -.
DR   OrthoDB; EOG091G00D2; -.
DR   PhylomeDB; Q8WYB5; -.
DR   TreeFam; TF106483; -.
DR   BRENDA; 2.3.1.48; 2681.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   SIGNOR; Q8WYB5; -.
DR   ChiTaRS; KAT6B; human.
DR   GeneWiki; MYST4; -.
DR   GenomeRNAi; 23522; -.
DR   PRO; PR:Q8WYB5; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000156650; -.
DR   CleanEx; HS_MYST4; -.
DR   Genevisible; Q8WYB5; HS.
DR   GO; GO:0070776; C:MOZ/MORF histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0000786; C:nucleosome; NAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IEA:InterPro.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0016573; P:histone acetylation; IDA:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; NAS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.10; -; 2.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR002717; HAT_MYST-type.
DR   InterPro; IPR005818; Histone_H1/H5_H15.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF01853; MOZ_SAS; 1.
DR   Pfam; PF00628; PHD; 1.
DR   SMART; SM00526; H15; 1.
DR   SMART; SM00249; PHD; 2.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS51504; H15; 1.
DR   PROSITE; PS51726; MYST_HAT; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Acyltransferase; Alternative splicing;
KW   Chromatin regulator; Chromosomal rearrangement; Complete proteome;
KW   Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   2073       Histone acetyltransferase KAT6B.
FT                                /FTId=PRO_0000051575.
FT   DOMAIN      103    176       H15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00837}.
FT   DOMAIN      715    989       MYST-type HAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01063}.
FT   ZN_FING     213    272       PHD-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     269    320       PHD-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     748    773       C2HC MYST-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01063}.
FT   REGION      361    717       Negatively regulates HAT activity.
FT   REGION      718   1008       Catalytic.
FT   REGION      752   1008       Interaction with BRPF1.
FT                                {ECO:0000269|PubMed:18794358}.
FT   REGION      856    860       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q92794}.
FT   REGION      865    871       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q92794}.
FT   REGION     1560   2073       Interaction with RUNX1 and RUNX2.
FT                                {ECO:0000269|PubMed:11965546}.
FT   COMPBIAS    492    533       Ser-rich.
FT   COMPBIAS    521    524       Poly-Ser.
FT   COMPBIAS    599    605       Poly-Ser.
FT   COMPBIAS   1070   1104       Poly-Glu.
FT   COMPBIAS   1204   1207       Poly-Glu.
FT   COMPBIAS   1351   1373       Poly-Glu.
FT   COMPBIAS   1409   1417       Poly-Glu.
FT   COMPBIAS   1594   1763       Ser-rich.
FT   COMPBIAS   1961   2061       Met-rich.
FT   ACT_SITE    891    891       Proton donor/acceptor.
FT                                {ECO:0000250|UniProtKB:Q9H7Z6}.
FT   BINDING     895    895       Acetyl-CoA.
FT                                {ECO:0000250|UniProtKB:Q92794}.
FT   SITE       1222   1223       Breakpoint for translocation to form
FT                                KAT6B-CREBBP.
FT   MOD_RES     355    355       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     647    647       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     815    815       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:Q92794}.
FT   MOD_RES    1038   1038       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1042   1042       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1044   1044       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1048   1048       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    673    673       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ     373    664       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10497217,
FT                                ECO:0000303|PubMed:9205841}.
FT                                /FTId=VSP_014586.
FT   VAR_SEQ     482    664       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10497217}.
FT                                /FTId=VSP_014587.
FT   VARIANT     360    360       E -> K. {ECO:0000269|PubMed:22077973}.
FT                                /FTId=VAR_067315.
FT   VARIANT     483    483       T -> A (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036361.
FT   VARIANT    1217   1217       A -> S (in dbSNP:rs57372986).
FT                                /FTId=VAR_061367.
FT   VARIANT    1499   1499       V -> I (in dbSNP:rs3740321).
FT                                /FTId=VAR_050217.
FT   CONFLICT    123    123       G -> R (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT    231    231       P -> A (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT    843    843       F -> L (in Ref. 1; AAF00095/AAF00099/
FT                                AAF00100 and 3; BAA20837). {ECO:0000305}.
FT   CONFLICT    931    933       TGM -> RHV (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT    934    934       Missing (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT   1152   1152       T -> S (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT   1625   1625       S -> T (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
FT   CONFLICT   1731   1731       S -> T (in Ref. 2; AAL56647).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2073 AA;  231378 MW;  AEE267B9DA444B08 CRC64;
     MVKLANPLYT EWILEAIQKI KKQKQRPSEE RICHAVSTSH GLDKKTVSEQ LELSVQDGSV
     LKVTNKGLAS YKDPDNPGRF SSVKPGTFPK SAKGSRGSCN DLRNVDWNKL LRRAIEGLEE
     PNGSSLKNIE KYLRSQSDLT STTNNPAFQQ RLRLGAKRAV NNGRLLKDGP QYRVNYGSLD
     GKGAPQYPSA FPSSLPPVSL LPHEKDQPRA DPIPICSFCL GTKESNREKK PEELLSCADC
     GSSGHPSCLK FCPELTTNVK ALRWQCIECK TCSACRVQGR NADNMLFCDS CDRGFHMECC
     DPPLSRMPKG MWICQVCRPK KKGRKLLHEK AAQIKRRYAK PIGRPKNKLK QRLLSVTSDE
     GSMNAFTGRG SPGRGQKTKV CTTPSSGHAA SGKDSSSRLA VTDPTRPGAT TKITTTSTYI
     SASTLKVNKK TKGLIDGLTK FFTPSPDGRR SRGEIIDFSK HYRPRKKVSQ KQSCTSHVLA
     TGTTQKLKPP PSSLPPPTPI SGQSPSSQKS STATSSPSPQ SSSSQCSVPS LSSLTTNSQL
     KALFDGLSHI YTTQGQSRKK GHPSYAPPKR MRRKTELSST AKSKAHFFGK RDIRSRFISH
     SSSSSWGMAR GSIFKAIAHF KRTTFLKKHR MLGRLKYKVT PQMGTPSPGK GSLTDGRIKP
     DQDDDTEIKI NIKQESADVN VIGNKDVVTE EDLDVFKQAQ ELSWEKIECE SGVEDCGRYP
     SVIEFGKYEI QTWYSSPYPQ EYARLPKLYL CEFCLKYMKS KNILLRHSKK CGWFHPPANE
     IYRRKDLSVF EVDGNMSKIY CQNLCLLAKL FLDHKTLYYD VEPFLFYVLT KNDEKGCHLV
     GYFSKEKLCQ QKYNVSCIMI MPQHQRQGFG RFLIDFSYLL SRREGQAGSP EKPLSDLGRL
     SYLAYWKSVI LEYLYHHHER HISIKAISRA TGMCPHDIAT TLQHLHMIDK RDGRFVIIRR
     EKLILSHMEK LKTCSRANEL DPDSLRWTPI LISNAAVSEE EREAEKEAER LMEQASCWEK
     EEQEILSTRA NSRQSPAKVQ SKNKYLHSPE SRPVTGERGQ LLELSKESSE EEEEEEDEEE
     EEEEEEEEED EEEEEEEEEE EEEENIQSSP PRLTKPQSVA IKRKRPFVLK KKRGRKRRRI
     NSSVTTETIS ETTEVLNEPF DNSDEERPMP QLEPTCEIEV EEDGRKPVLR KAFQHQPGKK
     RQTEEEEGKD NHCFKNADPC RNNMNDDSSN LKEGSKDNPE PLKCKQVWPK GTKRGLSKWR
     QNKERKTGFK LNLYTPPETP MEPDEQVTVE EQKETSEGKT SPSPIRIEEE VKETGEALLP
     QEENRREETC APVSPNTSPG EKPEDDLIKP EEEEEEEEEE EEEEEEEEGE EEEGGGNVEK
     DPDGAKSQEK EEPEISTEKE DSARLDDHEE EEEEDEEPSH NEDHDADDED DSHMESAEVE
     KEELPRESFK EVLENQETFL DLNVQPGHSN PEVLMDCGVD LTASCNSEPK ELAGDPEAVP
     ESDEEPPPGE QAQKQDQKNS KEVDTEFKEG NPATMEIDSE TVQAVQSLTQ ESSEQDDTFQ
     DCAETQEACR SLQNYTRADQ SPQIATTLDD CQQSDHSSPV SSVHSHPGQS VRSVNSPSVP
     ALENSYAQIS PDQSAISVPS LQNMETSPMM DVPSVSDHSQ QVVDSGFSDL GSIESTTENY
     ENPSSYDSTM GGSICGNGSS QNSCSYSNLT SSSLTQSSCA VTQQMSNISG SCSMLQQTSI
     SSPPTCSVKS PQGCVVERPP SSSQQLAQCS MAANFTPPMQ LAEIPETSNA NIGLYERMGQ
     SDFGAGHYPQ PSATFSLAKL QQLTNTLIDH SLPYSHSAAV TSYANSASLS TPLSNTGLVQ
     LSQSPHSVPG GPQAQATMTP PPNLTPPPMN LPPPLLQRNM AASNIGISHS QRLQTQIASK
     GHISMRTKSA SLSPAAATHQ SQIYGRSQTV AMQGPARTLT MQRGMNMSVN LMPAPAYNVN
     SVNMNMNTLN AMNGYSMSQP MMNSGYHSNH GYMNQTPQYP MQMQMGMMGT QPYAQQPMQT
     PPHGNMMYTA PGHHGYMNTG MSKQSLNGSY MRR
//
